Achieving very low levels of low-density lipoprotein cholesterol while on statin treatment may reduce the risk for cardiovascular disease in people with type 2 diabetes and metabolic dyslipidemia, suggest the results of a large observational study.

A population-based study suggests that treatment with a statin may slow the risk for new and worsening retinopathy in patients with diabetes and dyslipidemia.

Data from the ODYSSEY series of trials, presented at the American Diabetes Association scientific sessions, show that the PCSK9 inhibitor alirocumab reduces atherogenic dyslipidemia in patients with diabetes.

The effect of the PCSK9 inhibitor alirocumab on dyslipidemia in patients with type 1 diabetes is consistent with that seen in the type 2 population, the ODYSSEY team has revealed.

Real-world study data show that non-fasting remnant cholesterol levels are associated with a significantly increased risk for CVD in people without diabetes, with a similar, but nonsignificant, trend observed in those with diabetes.

People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.

Indeed, dyslipidemia prevalence rose in all age groups younger than 60 years.

For cardiometabolic risk factors, the investigators report that people who had two parents with diabetes were a significant 12% more likely to have hypertension and 21% more likely to have dyslipidemia than those with no family history, after adjusting for potential confounders.

The proportion of participants with hypertension rose from 19.2% at baseline to 67.5% at the 15-year follow-up, while the proportion with dyslipidemia increased from 20.8% to 51.6%.

He stresses the need for the monitoring for and, where needed, treatment of hypertension, dyslipidemia, sleep apnea, and kidney disease.

The iCount study was set up as an offshoot of the TODAY2 study , which showed that young people with an early diagnosis of type 2 diabetes appear to be rapidly accumulating complications including dyslipidemia, hypertension, broader cardiovascular disease, kidney disease, retinopathy, and poor pregnancy outcomes.

For obesity and dyslipidemia, the PAR% was zero by age 75 years, compared with 15.9% and 8.7%, respectively, among the youngest participants.

In contrast with the cardiorenal outcomes, retinopathy outcomes were concentrated in a cluster of people who had high blood pressure, “moderately elevated” HbA1c levels, and dyslipidemia.

Future risk for type 2 diabetes or cardiovascular disease may be determined by a person’s lipid profile, suggests research published in PLOS Biology .

Almost two in every five patients receiving treatment for hypertension or dyslipidemia have undetected dysglycemia, shows an analysis of the EUROASPIRE IV registry.

One of the comorbidities had to be hypertension or dyslipidemia; in addition, a subset of Japanese participants, comprising 25% of the total trial population, had type 2 diabetes.

An analysis in JAMA shows that the price of PCSK9 inhibitors, recently shown to be effective against diabetic dyslipidemia, will need to fall by nearly three-quarters before they can be considered cost-effective even in high-risk patients with established cardiovascular disease.